Formulary Monographs [DAPAGLIFLOZIN, 682018]
|
|
DAPAGLIFLOZIN
|
|
|
|
|
|
SODIUM-GLUCOSE COTRANSPORTER INHIBITOR
|
|
|
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
|
|
|
Back pain; balanoposthitis; dizziness; dyslipidaemia; hypoglycaemia (in combination with insulin or sulphonylurea); increased risk of genital mycotic infection in both males and females; rash; increase risk of urinary disorders.
|
|
|
The usual oral dose is 5 or 10 mg once daily. Doses of insulin, sulfonylurea, and other insulin secretagogues may need to be lowered when used with dapagliflozin. The dose of dapagliflozin should be reduced in hepatic impairment.
|
|
|
|
|
|
|
|
|
|
|
|
|